中华消化杂志
中華消化雜誌
중화소화잡지
Chinese Journal of Digestion
2009年
9期
554-558
,共5页
唐平飞%李瑾%贺文成%周瑞%夏冰
唐平飛%李瑾%賀文成%週瑞%夏冰
당평비%리근%하문성%주서%하빙
结肠炎%溃疡性%吉法酯%氨基水杨酸%环氧化酶-1%环氧化酶-2
結腸炎%潰瘍性%吉法酯%氨基水楊痠%環氧化酶-1%環氧化酶-2
결장염%궤양성%길법지%안기수양산%배양화매-1%배양화매-2
Colitis,ulcerative%Gefarnate%Aminosalicylic acid%Cyclooxygenase 1 Cyclooxygenase 2
目的 观察吉法酯对三硝基苯磺酸(TNBS)诱导的大鼠实验性结肠炎髓过氧化物酶(MPO)、环氧合酶(COX)-1及COX-2表达的影响,探讨吉法酯对溃疡性结肠炎的治疗作用.方法 选用雌性健康SD大鼠40只,均分为A、B、C、D组.A、B、C三组大鼠采用TNBS/乙醇灌肠制作大鼠结肠炎模型.造模后第2天,A组每天给予0.9%氯化钠溶液1 ml灌肠;B组每天给予5-氨基水杨酸(5-ASA)1 ml灌肠(100 mg/kg);C组每天给予吉法酯1 ml灌胃.D组为正常对照组.分别于造模后第7天及第14天每组处死5只大鼠,按疾病活动指数(DAI)的评分标准进行大体损伤评分,HE染色进行组织损伤评分.同时取结肠病变部位组织,生化法检测MPO活性,免疫组化法检测COX-1与COX-2的组织表达.结果 与A组比较,B组和C组的DAI评分、大体损伤形态和组织学损伤评分及MPO活性均降低(P<0.05).与A组相比,B、C、D组第7天和第14天COX-1表达水平升高(P<0.05),分别为0.87±0.18和0.93±0.15比1.86±0.51和1.96±0.41,1.73±0.68和1.79±0.6以及1.91±0.34和1.99±0.45;COX-2水平降低(P<0.05),分别为3.50±0.23和3.06±0.27比1.53±0.19和0.73±0.15,1.73±0.94和0.86±0.29,0.24±0.18和0.18±0.16.D组COX-2表达极弱,与B、C两组间差异有统计学意义(P<0.05).结论 吉法酯对TNBS诱导的大鼠结肠炎有较好的治疗作用,其疗效与5-ASA相似,其作用机制可能是降低肠组织中MPO的活性和调节COX-1/COX-2表达.
目的 觀察吉法酯對三硝基苯磺痠(TNBS)誘導的大鼠實驗性結腸炎髓過氧化物酶(MPO)、環氧閤酶(COX)-1及COX-2錶達的影響,探討吉法酯對潰瘍性結腸炎的治療作用.方法 選用雌性健康SD大鼠40隻,均分為A、B、C、D組.A、B、C三組大鼠採用TNBS/乙醇灌腸製作大鼠結腸炎模型.造模後第2天,A組每天給予0.9%氯化鈉溶液1 ml灌腸;B組每天給予5-氨基水楊痠(5-ASA)1 ml灌腸(100 mg/kg);C組每天給予吉法酯1 ml灌胃.D組為正常對照組.分彆于造模後第7天及第14天每組處死5隻大鼠,按疾病活動指數(DAI)的評分標準進行大體損傷評分,HE染色進行組織損傷評分.同時取結腸病變部位組織,生化法檢測MPO活性,免疫組化法檢測COX-1與COX-2的組織錶達.結果 與A組比較,B組和C組的DAI評分、大體損傷形態和組織學損傷評分及MPO活性均降低(P<0.05).與A組相比,B、C、D組第7天和第14天COX-1錶達水平升高(P<0.05),分彆為0.87±0.18和0.93±0.15比1.86±0.51和1.96±0.41,1.73±0.68和1.79±0.6以及1.91±0.34和1.99±0.45;COX-2水平降低(P<0.05),分彆為3.50±0.23和3.06±0.27比1.53±0.19和0.73±0.15,1.73±0.94和0.86±0.29,0.24±0.18和0.18±0.16.D組COX-2錶達極弱,與B、C兩組間差異有統計學意義(P<0.05).結論 吉法酯對TNBS誘導的大鼠結腸炎有較好的治療作用,其療效與5-ASA相似,其作用機製可能是降低腸組織中MPO的活性和調節COX-1/COX-2錶達.
목적 관찰길법지대삼초기분광산(TNBS)유도적대서실험성결장염수과양화물매(MPO)、배양합매(COX)-1급COX-2표체적영향,탐토길법지대궤양성결장염적치료작용.방법 선용자성건강SD대서40지,균분위A、B、C、D조.A、B、C삼조대서채용TNBS/을순관장제작대서결장염모형.조모후제2천,A조매천급여0.9%록화납용액1 ml관장;B조매천급여5-안기수양산(5-ASA)1 ml관장(100 mg/kg);C조매천급여길법지1 ml관위.D조위정상대조조.분별우조모후제7천급제14천매조처사5지대서,안질병활동지수(DAI)적평분표준진행대체손상평분,HE염색진행조직손상평분.동시취결장병변부위조직,생화법검측MPO활성,면역조화법검측COX-1여COX-2적조직표체.결과 여A조비교,B조화C조적DAI평분、대체손상형태화조직학손상평분급MPO활성균강저(P<0.05).여A조상비,B、C、D조제7천화제14천COX-1표체수평승고(P<0.05),분별위0.87±0.18화0.93±0.15비1.86±0.51화1.96±0.41,1.73±0.68화1.79±0.6이급1.91±0.34화1.99±0.45;COX-2수평강저(P<0.05),분별위3.50±0.23화3.06±0.27비1.53±0.19화0.73±0.15,1.73±0.94화0.86±0.29,0.24±0.18화0.18±0.16.D조COX-2표체겁약,여B、C량조간차이유통계학의의(P<0.05).결론 길법지대TNBS유도적대서결장염유교호적치료작용,기료효여5-ASA상사,기작용궤제가능시강저장조직중MPO적활성화조절COX-1/COX-2표체.
Objective To investigate the effects of Gefarnate on expression of myeloperoxidase (MPO),cyelooxygenase-1 (COX-1) and COX-2 in trinitrobenzene sulphonic acid (TNBS) induced experimental colitis in rats and its therapeutic effects on ulcerative colitis. Methods Forty female Sprague-Dawley (SD) rats were randomly divided into 4 groups with 10 each. The rats in group A, B and C were infused with TNBS/alcohol by enema. After the production of colitis, the rats in group A or B were treated daily with 1 ml of normal saline or with 1 ml of 5-ASA (100 mg/kg) by enema,and those in group C were treated daily with 1 ml of Gefarnate by gavage. Group D was served as normal control. After the production of colitis,animals were sacrificed at day 7 and 14 with 5 in each group. The macroscopic changes of the colon were evaluated according to disease activity index (DAD scoring and histological change was assessed by HE staining. MPO activity of the mucosa was detected by biochemical methods. Expressions of COX-1 and COX-2 in tissues were detected by immunohistochemistry. Results Compared with group A, macroscopic and histological scores and MPO activity were significantly decreased in group B and C (P<0.05). The expressions of COX-1 at day 7 and 14 were 1.86±0.51 and 1.96±0.41 in group B, 1.73±0.68 and 1.79±0.6 in group C, 1.91±0.34 and 1.99±0.45 in group D, respectively, which were significantly higher than those in group A (0.87±0.18 and 0.93±0.15, P<0.05). Whereas the expressions of COX-2 at day 7 and 14 were 1.53±0.19 and 0.73±0.15 in group B, 1.73±0.94 and 0.86±0.29 in group C, 0.24±0.18 and 0.18±0. 16 in group D, respectivley, which were significantly lower that those in group A (3.50±0.2;3 and 3.06±0.27). There was a significant difference between group D and group B or C (P<0.05). Conclusions Gefarnate provides a therapeutic effect during TNBS-induced colitis in rats, which is similar to that of 5-ASA. The mechanisms are involved in decreasing the concentration of colonic MPO and regulating the expression of COX-1/COX-2.
